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General Abstract 
There has been a steady increase in the use of medicinal plants in the last two decades in both 
developed and developing countries for prevention, management and treatment of diseases. This 
increase has been due to reasons such as ease of access, better cultural acceptability and 
compatibility, cost effectiveness and also the bid to “go natural”. Unfortunately, the notion that 
herbal medicines are relatively safe because they are natural has led to serious and potentially 
fatal consequences in phytotherapy. The lack of rigorous research to prove the effectiveness and 
safety of many medicinal plants is of great concern to the health care system.  
 
This thesis therefore addresses not just the efficacy, but also the safety of the extracts of the berry 
of Solanum aculeastrum - a medicinal plant used, among other things, for the treatment of breast 
cancer in the Eastern Cape Province of South Africa. Particular attention was paid to the possible 
effect of different processing methods of the berry extracts on inflammation, cytotoxicity, and 
toxicity. In studying the comparative effects of various processing methods, four different 
preparations of the extracts were investigated. These include fresh, dried, boiled fresh, and boiled 
dried berries. While the effect of processing on the anti-inflammatory properties of the extracts 
was not dose dependent, the percentage reduction in inflammation was highly significant and 
more prominent in both concentrations of the boiled fresh berries than the reference drug, 
indomethacin. Furthermore, the four extracts varied in their ability to act either centrally or 
peripherally in their effect on pain. Assessment of the analgesic response using the formalin test 
showed that, at both concentrations tested, none of the extracts inhibited the first phase of the 
formalin test. Furthermore, it was observed that boiling had differing results on the activity of the 
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fresh and dried extracts. While boiling of the dried berries reduced pain in the rats, the opposite 
trend was observed with the boiled fresh berries. Results of the influence of processing of the 
berries on cytotoxicity indicated that the extracts are potent inhibitors of human breast, cervical 
and colonic carcinoma cells and the non-cancerous cells (both the actively dividing and 
confluent Chang liver cells). Although, in terms of relative potency, the fresh berries appeared to 
be the most active of the extracts, processing of the berries caused an increase in apoptotic cells 
and a subsequent decrease in the necrotic cells. The effect of processing on the safety of the 
berry of S. aculeastrum on the rats fed for 28 days was also investigated. The various doses (1, 
10 and 25 mg/kg body weight) of all the four extracts did not alter the activity and the weight of 
the animals throughout the period of treatment. A reduction in organ to body weight ratio of the 
heart, kidney, liver and spleen was observed in all the extracts. Regarding the haematological 
parameters, different patterns of effect were observed between the extracts and within the treated 
doses. The observed alterations in the biochemical parameters by the various extract of Solanum 
aculeastrum berries at all the doses may have consequential effects on the normal functioning of 
these organs.  
 
In conclusion, this study has shown that there is some justification for the traditional use of the 
berries of Solanum aculeastrum in the treatment of inflammation related ailments and cancer. 
However, the medicinal use of the plant also poses considerable health risks. Investigation 
conducted into the plant’s safety revealed that the berry extracts were nephrotoxic, hepatotoxic, 
haematotoxic and at higher doses, fatal.  Another concern with regard to the plant’s safety is the 
non-selectivity of its extracts in the inhibition of carcinoma, actively dividing and un-dividing 
cells. Assessment of the effect of the processing on the berry’s efficacy and safety as herbal 
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remedy produced mixed results. On the one hand, processing seemed to improve the extract’s 
anti-inflammatory and analgesic activity, while reducing its cytotoxic potential. On the other 
hand, a reduction in the toxicity was observed on the processed extracts compared to the fresh 
ones. This may be an indication that processing has an overall beneficial effect on the medicinal 
properties of the plant and should thus be considered as a method of making the berries of 
Solanum aculeastrum safer for use as a herbal remedy.  
 
Keywords: Medicinal plants, Solanum aculeastrum, efficacy, safety, processing, cytotoxicity, 
toxicity. 
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1.0 Introduction 
1.1 General overview of cancer and its treatment 
The human adult is comprised of about 1015 cells, many of which are required to divide and 
differentiate in order to repopulate organs and tissues which require cell turnover (Bertram, 
2001). The ability of the body to control cell multiplicity is achieved by a network of 
overlapping molecular mechanisms which direct cell proliferation and death. Any alteration in 
this balance (birth and death of cells), has a potential, if uncorrected, to alter the number of cells 
in an organ or tissue. Such changes may result in cancer, a disease that is manifested in many 
forms depending primarily on the organ from which it evolves. Characteristically, cancer is 
defined as the uncontrolled proliferation of cells which become structurally abnormal and 
possess the ability to detach themselves from a tumor and establish a new tumor at a remote site 
within the host (National Cancer Institute (NCI), 2009). 
 
Globally, cancer is one of the leading causes of death. According to the American Cancer 
Society (ACS), an estimation of about 1,500,000 new cases and over 500,000 deaths are 
expected to be recorded in the US in 2009 (ACS, 2009). South Africa experiences one of the 
highest incidence rates of cancer in Africa (Mqoqi et al., 2004). Every one in four males and six 
females have the potential of developing cancer. The current statistics by the National Cancer 
Registry of South Africa indicate that cancers of the bladder, colon, breast, cervix, lungs and 
melanoma are among the most common (Mqoqi et al., 2004). 
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The existing strategy of eradicating cancer after detection has resulted in mortality that may have 
been preventable if caution was taken against the causative agents (Doll and Peto, 1981). 
Although, the etiology of cancer remains unknown to an extent, epidemiology has suggested the 
hypotheses that multiple causative factors may be operating. These factors (exogenous and 
endogenous) exert their specific effects at different times in the life of the patient. The impact of 
such effects might be cumulative or synergistic. The main predictors of the incidence of cancer 
fall largely into two broad categories: environmental and positive family history (Parkin et al., 
2005). A number of other risk factors exist from a wide range of studies in various populations 
and geographic locations. 
 
The progress in research on the etiology of cancer has revealed the evidence that dietary patterns, 
nutrients and food constituents are closely associated with the risk of several types of cancer 
(Doll and Peto, 1981). Fat has been the focus of nutritional studies on cancers of the prostate, 
breast and colon more than any other dietary component (National Research Council, 1989). 
Several studies in countries consuming high fat diets have consistently shown higher incidence 
and mortality rates for breast, colon and prostate cancers (National Research Council, 1989; 
Hursting et al., 1990). Studies of specific environmental influences have suggested an increased 
risk of developing various forms of cancer with exposure to particulate air pollutants and 
fertilizers. Substances such as asbestos, aniline dye, uranium and nickel have been implicated as 
environmental carcinogens (Monson and Christiani, 1997).  
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1.2 The role of inflammation in the initiation of cancer 
The association between inflammation and tumor has long been known (Balkwill and 
Mantovani, 2001). Since then, inflammation is increasingly recognized as an important 
component of several cancers, although the mechanisms involved are not fully understood (Ben-
Baruch, 2006). A vast body of evidence has indicated that inflammatory leucocytes contribute to 
cancer development either directly by the release of vesicle stored growth and survival factors 
and diverse proteolytic enzymes, or indirectly via the activation of cell signaling cascades as a 
result of altered pericellular matrix remodelling activity (van Kempen et al., 2006).  Products of 
inflammation such as growth factors, cytokines and transcription factors, like nuclear factor-
kappa B (NF-κB), control the expression of cancer genes and key inflammatory enzymes such as 
inducible nitric oxide (iNOS) and cyclooxygenase-2 (COX-2) (Hofseth and Ying, 2006). 
 
Bacterial, viral and parasitic infections, chemical irritants and non-digestible particles are some 
of the causes of chronic inflammation. The longer this inflammation persists, the higher the risk 
of associated carcinogenesis (Shacter and Weitzman, 2002). Chronic inflammation occurs due to 
environmental stress around the tumor, thus generating a shield protecting the tumor from the 
immune system (Assenat et al., 2006). Recent demonstrations have shown that micro-
environment of tumors highly resemble an inflammation site, with a significant tendency for 
tumor progression (Assenat et al., 2006). In addition, this micro-environment apart from its 
significant role in cancer progression and protection, has a considerable adverse effect on the 
success of the various current cancer treatments (Assenat et al., 2006). The pro-cancerous 
outcome of chronic inflammation are increased DNA damage, increased DNA synthesis, cellular 
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proliferation, the disruption of DNA repair pathways and cellular milieu, the inhibition of 
apoptosis, the promotion of angiogenesis and invasion (Hofseth and Wargovich, 2007). 
Therefore, inflammation plays a major role in the initiation and progression of cancers. 
 
Inflammatory-related ailments are treated mainly with non-steroidal anti-inflammatory drugs 
(NSAIDs). These drugs are used to reduce the consequences of inflammation (Vane and Botting 
1996). Indomethacin, an NSAID, for example has been found to block carcinogenesis in animals 
by reducing the production of inflammatory cytokines (Federico et al., 2007). A lower risk of 
cancer incidence has also been found in people regularly taking NSAIDs (Fosslien, 2000). 
 
1.3 Treatment options for cancer 
The treatment option for cancer is influenced by several factors, such as the specific nature of the 
cancer; the status of the patient (age and health); and whether the goal of treatment is eradication 
of the tumor, control of the local tumor growth, prolongation of survival or palliation of cancer 
symptoms (NCI, 2009). Depending on these factors, treatment options such as surgery, 
chemotherapy, radiation and hormonal therapy could be used. More than half of all people 
diagnosed with cancer are treated with chemotherapy because it is considered a systemic 
treatment. The cancer-fighting drugs circulate in the blood to parts of the body where the cancer 
may have spread and can kill or eliminate cancers cells at sites of great distances from the 
original cancer. The side effects observed with these treatments may be severe, thus reducing the 
quality of life, compromising treatment and sometimes limiting the chance for an optimal 
outcome from treatment. Common side effects includes anaemia, depression, fatigue, hair loss, 
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infections, low blood counts, nausea and vomiting and long term effects such as cardiac toxicity, 
growth problems and sterility (NCI, 2009).  
1.3.1 Phytotherapy for cancer treatment 
Despite the major scientific and technological progress in the treatment and management of 
cancer, no reliable and definitive cure has been found (Richardson, 1999). This has led to an 
increase in the dependence of patients on unconventional medical therapies (Alschuler et al., 
1997). All over the world, the traditional use of plants in the treatment of ailments has been on 
the increase especially in developing countries where there is invariably poor availability of 
primary health care (Alschuler et al., 1997).  
 
Plants are a viable source of biologically active natural products which have served as 
commercial drugs or as lead structures for the development of modified derivatives possessing 
enhanced activity (Cordell et al., 1991). Extracts of plants have a long history of use in the 
treatment of cancer (Hartwell, 1982). Over 60% of the currently used anticancer agents are 
derived in one way or the other from natural sources including plants and marine organisms 
(Cragg and Newman, 2005). For example, the breakthrough for cancer treatment was achieved 
by the discovery and development of the vinca alkaloids, vincristine and vinblastine isolated 
from Catharanthus roseus in the early 1950’s (Cragg et al., 1994). The discovery of these 
chemicals led to other research where compounds such as podophyllotoxin derivatives, etoposide 
and teniposide from the root of various Podophyllum species (Gurib-Fakim, 2006) and paclitaxel 
from the bark of Taxus brevifolia (Kingston, 2005) were isolated (Fig 1). Other examples include 
the camptothecin derivatives (topotecan, irinotecan and 9- aminocamptothecin) isolated from 
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Camptotheca acuminata, homoharringtonine from Cephalotaxus harringtonia var drupaceae and 
elliptinium from several genera in the Apocyanaceae family (Wall, 1998; Kuo and King, 2001). 
Since then, various studies have been undertaken to discover more natural sources of drugs for 
the treatment of cancer.  
1.4 Efficacy and safety of medicinal plants 
The traditional use of plants in the treatment of ailments has been on the increase both in 
developing countries, where there is poor availability of primary health care, and also in the 
developed world. Herbal medicines are in great demand in the developing world for primary 
health care not only because they are inexpensive but also for better cultural acceptability, better 
compatibility with the human body and minimal side effects. This is primarily due to the general 
belief that herbal medicines are relatively safe because they are natural (Gesler, 1992).  
 
The knowledge of the healing virtues of medicinal plants has been passed on from ancient times. 
History tells of medicinal plants such as Catharanthus roseus G. Don, Digitalis purpurea Linn, 
Rauwolfia serpentina Plum ex Linn, Willow (Salix species), Physostigma venenosum Balf. and a 
host of other plants which have been used for centuries for the treatment of diseases such as 
cancer, cardiovascular diseases, hypertension, depression, pain, glaucoma and an array of other 
diseases that have plagued the world. Since then, plants have served as viable sources of 
biologically active natural products which are either used as commercial drugs or as lead 
structures for the development of modified derivatives possessing enhanced activity (Cordell et 
al., 1991). Modern medicine as a result of civilization led to the reduced importance of medicinal 
plants to human survival. This was not because these plants were ineffective but because they  
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Figure 1: Plant derived anticancer agents currently in clinical use
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were not economically profitable as the newer synthetic drugs (Tyler, 1999). However, in recent 
times, the concerns over the serious adverse effect of conventional drugs and the movement 
towards a more natural living has brought about a resurgence in the use of herbal products (Pal 
and Shukla, 2003).  
 
The number of patients seeking herbal approaches for therapy has grown exponentially 
(Alschuler et al., 1997). This has, for example increased the number of medical doctors in France 
and Germany that regularly prescribe herbal medicine to 70% (Murray and Pizzorno, 2000). 
Available records have illustrated the growth of the herbal medicine market in the European 
Union countries. In 1991, sales were about $ US 6 billion, with Germany accounting for $ US3 
billion, France $ US 1.6 billion and Italy $ US 0.6 billion while in the US, herbal medicine 
market was about $ 4 billion in 1996 (Pal and Shukla, 2003). India boasts about $ US 80 million 
for the exportation of herbal crude extracts (Kamboj, 2000). The resurgence and popularity of 
herbal medicines have led to an increase in the number of medicinal plant products in the market 
(Gupta and Raina, 1998). Unfortunately, the increased dependence on phytotherapy, without 
concern for efficacy and safety has resulted in preventable serious adverse effects (Gurib-Fakim, 
2006).  
 
1.4.1 Efficacy of medicinal plants 
With the slight increase in the randomized controlled trials to evaluate the efficacy of herbal 
medicines, an estimate of about 39% of all 520 new approved drugs were natural products or 
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derived from natural products in 1983-1994 (Cragg et al., 1997). The study of Harvey (1999), 
reported that 60-80% of antibacterial and anticancer drugs were derived from natural products. 
The antimalaria quinine from Cinchona officinalis, analgesics codeine and morphine from 
Papaver somnifera, antihypertensive reserpine from Rauwolfia serpentina and cardiac glycoside 
digoxin from Digitalis pupurea are some of the many drugs derived from medicinal plants that 
have been in use. The fact remains that plant substances constitute the basis for a very large 
proportion of medications used today for the treatment of diseases of the liver and heart, cancer, 
hypertension, depression and other ailments. This is the result of an increase in the scientific 
studies carried out to validate the traditional claims of these plants (Gurib-Fakim, 2006).  
 
1.4.2 Safety of medicinal plants 
Recent findings indicate that herbal medicines may not be safe and severe consequences have 
arisen from the use of certain products (Gurib-Fakim, 2006; Bush et al., 2007). Information 
obtained from health centres and hospital emergency rooms have shown that 5 % of patients 
receiving complementary therapies report side effects (Molassiotis et al., 2005). The true 
frequency of the incidence of side effects from herbal remedies may be several folds higher than 
this (Ernst, 2004), because the lack of surveillance systems which are less extensive than for 
conventional drugs have limited these reports (Bent and Ko, 2004). For example, acute poisoning 
as a result of herbal medicines is estimated to cause anywhere from 8,000 to 20,000 deaths 
annually in South Africa (Thomson, 2000). These side effects may occur through several 
different mechanisms, including direct toxic effects of the herbs, effects of contaminants, and 
interactions with drugs or other herbs (Niggemann and Gruber, 2003; Bent and Ko, 2004; Ernst, 
2004). The risk of herbal remedies producing side effects depends not only on the herb and the 
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dose consumed, but also on the health status and age of the patient and the concurrent use of 
other drugs (De Smet, 1995).  
1.4.2.1 Direct toxic effects of medicinal plants 
Serious and potentially fatal adverse effects can occur with the use of herbal remedies. 
Unfortunately, patients who experience such side effects may not associate them with their use 
of herbal medicines (Pal and Shukla, 2003). This is further complicated by the fact that the 
majority of these drugs are self-prescribed and never mentioned when patients consult the 
doctors (Bent and Ko, 2004), resulting in the under-reporting of adverse reactions associated 
with herbal preparations. 
 
Gupta and Raina, (1998) reviewed the side effects of some medicinal plants. Their study listed 
21 popular medicinal plants such as garlic, licorice, senna and digitalis used in the treatment of 
various diseases. Toxic symptoms such as respiratory distress, raised blood pressure, paralysis of 
the central nervous system, dermatitis, nephrotoxicity, hepatotoxicity and ultimately death were 
recorded from the use of these plants. Hepatic failure and even death, following ingestion of 
herbal medicines was also reported by Chattopadhyay, (1996). Studies have shown that 25% of 
corneal ulcers in Tanzania and 26% of childhood blindness in Nigeria and Malawi were 
associated with the use of traditional eye medicine (Harries and Cullinan, 1994). Vickers and 
Zollman, (1999) reported the development of rapidly progressive interstitial renal fibrosis by 
several women after taking Chinese herbs prescribed by a slimming clinic. Doctors in Belgium 
discovered that a Chinese herb, Aristolochia fangchi was not only linked to kidney failure, but 
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also cancer (Kew et al., 1993). Table 1 shows a summary of some commonly used medicinal 
plants with adverse effects. 
1.4.2.2 Effect of contaminants 
Side effects due to contamination in herbal products have mainly been recorded in Asian herbal 
remedies. Kew et al., (1993) and De Smet, (1997) reported the presence of mercury, lead, 
arsenic, corticosteroids and poisonous organic substances in harmful amounts in herbal remedies. 
These results were also observed when Ko, (1998), examined 260 of the patent drugs in Asia and 
found that 25% contained high level of heavy metals such as mercury, lead or arsenic and 7% 
contained undeclared pharmaceutical drugs to enhance the desired effects.  A good example is 
PC-SPES (a combination of 8 medicinal plants), a formulated drug for the treatment of prostate 
cancer. Investigations into this remedy resulted in the detection of varying amount of synthetic 
drugs such as warfarin, indomethacin, diethylstilbestrol and ethinyl estradiol which ultimately 
led to its removal from the herbal market (Ko et al., 2003). 
1.4.2.3 Interaction with other herbs and drugs 
A typical example of a herbal remedy which, on interaction with other herbs or drugs, caused 
varying levels of toxicity is St. John’s wort (Hypericum perforatum) (Ernst, 2004). Extracts of 
this plant have been used traditionally for the treatment of wounds and burns, or taken orally as 
an infusion or tea to treat fevers and nervous conditions including depression (Tonbridge, 1999). 
Preparations of St John's wort in Europe and the United States are bought over-the-counter for 
the treatment of a variety of conditions. However, recent indications of side effects and also 
interactions with other drugs, resulting in potentially serious adverse effects, have put questions 
marks on its safety. Adverse effects such as gastrointestinal symptoms, allergic reactions, 
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dizziness, confusion, tiredness, sedation and dry mouth have been associated with this remedy 
(Ernst et al., 1998; Woelk et al., 1994). The interaction between St. John’s wort and drugs such 
as warfarin or phenoprocumon, cyclosporine, theophylline, digoxin, HIV protease inhibitors 
(indinavir and lamivudine) and oral contraceptives have been found to cause clinically 
significant consequences such as the rejection of a transplanted organ, reduction in the efficacy 
of these drugs and failure in treatment (Dasgupta and Bernard, 2006). Other common herbal 
remedies worth mentioning include garlic, ginger, ginseng, ginkgo and feverfew which interact 
with warfarin leading to changes in its effectiveness (Dasgupta and Bernard, 2006). 
1.5 Aims and objectives of this study 
The primary aim of this work is to examine the effect of processing on the efficacy and safety of 
Solanum aculeastrum berries as remedy for inflammation and cancer. The specific objectives 
include: 
1. In vivo anti-inflammatory and analgesic activity 
2. In vitro anticancer activity based on the following parameters: cytotoxic assay (cell 
growth inhibition), apoptosis determination, cell cycle/cell death analysis and 
3. Toxicological and histopathological evaluation of the extracts from the berries of this 
plant. 
4. Investigation into the effect of processing on the efficacy (as an anti-inflammatory and 
anti-cancer agent) and safety of Solanum aculeastrum berries.  
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Table 1: Common medicinal plants and their adverse effects 
Medicinal plant  Common uses              Side effects     References 
Cassia senna      Laxative   Carcinogenic, hepatotoxicity, hepatitis  Dasgupta & Bernard, 2006;  
               Gupta & Raina, 1998 
Urtica dioica      Genitourinary ailments            Uterine-stimulant effect, induction of   De Smet, 2002. 
          abortion  
Matricaria chamomilla Migraine, bronchitis, fever,  Allergic reactions and conjunctivitis   De Smet, 2002;  
    Gastrointestinal tract ailments      Gupta & Raina, 1998   
   
Allium sativum  Hypercholesterolemia, cough,   Death at a dose of 10mg/100g   Dasgupta & Bernard 2006; 
asthma, chronic bronchitis    body weight intragastrically to rats,     Gupta & Raina, 1998 
        hepatotoxicity 
Piper methysticum  Sleeping aid, anti-anxiety Hepatotoxicity, kidney damage,     Dasgupta & Bernard 2006;  
                                                                                                loss of  muscle control     Ernst, 2004. 
Glycyrrhiza glabra  Bronchitis, chronic gastritis, Heart failure, hypertension, sodium    Dasgupta & Bernard 2006; 
                peptic ulcer    and water retention, weight gain    Gupta & Raina, 1998 
Larrea tridentate  Diabetes, rheumatism, Hepatotxicity, nephrotoxicity, carcinogenic   Dasgupta & Bernard 2006; 
                                     infertility, kidney and gall         O’Hara et al., 1998 
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bladder stones, anticancer 
Catharanthus roseus Diabetes, cancer chemotherapeutic Male reproductive system toxicity,                   Fennell et al., 2004                         
        DNA damage and chromosomal damage    Gupta & Raina, 1998 
Callilepis laureola Stomach complaints, induce fertility Liver necrosis, nephrotoxicity, carcinogenic,     Popat et al., 2001 
   impotence, cough remedy  death    
Aristolochia fangchi  Weight loss, rheumatism, oedema Nephrotoxicity, carcinogenic     Niggemann & Gruber, 2003 
Datura stramonium Anaesthesia, eye drops, spasm, Blurred vision, delirium, incoherence,    Kurzbaum et al., 2001 
   motion sickness, parkinsonism coma, death 
Atropa belladonna Relaxant, antiulcer   Anticholinergic, central nervous system    O’Hara et al. 1998; 
        and respiratory depression 
Ephedra sinica  Anorectic, stimulant,   Associated with hypertensive stroke,     Dasgupta & Bernard, 2006 
                                                    
   bronchodilator    palpitations, and nerve damage, death     O’Hara et al., 1998 
 
Viscum album             Antihypertensive, antitumor  Central nervous system and cardiac toxic      O’Hara et al., 1998;  
reaction, gastrointestinal bleeding       Gupta & Raina, 1998 
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1.6 Scope of the study 
This study starts with the review of previous studies done on S. aculeastrum. It includes the 
investigation of the anti-inflammatory and analgesic potential of fresh and processed (dried, 
boiled dried and boiled fresh) extracts of the plant’s berries in vivo. This is important because 
anti-inflammatory treatments have been found to block carcinogenesis (Federico et al., 2007) 
leading to lower risk of cancer incidence in people regularly taking them (Fosslien, 2000). The 
cytotoxic effect of these extracts on human tumours such as HeLa, MCF-7, HT-29, as well as 
healthy Chang liver cell line using the MTT assay was also studied. In addition, the induction of 
apoptosis and cell cycle arrest was monitored using Annexin V–FITC Apoptosis Detection Kit. 
Toxicological studies, specifically the effect of the extracts on the organs as well as on the 
haematological and biochemical parameters of male Wistar rats were studied for 14 and 28 days 
respectively. 
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2.0 Introduction 
The choice of this plant (Solanum aculeastrum) for the present study emanated from the 
conclusions derived from the PhD thesis of Koduru (2006), who validated the traditional use of 
the plant in the treatment of cancer in vitro. In 2005, this author conducted an ethnobotanical 
survey of the plants used in the treatment of cancer by the people of the Eastern Cape Province in 
South Africa and one of such plants was S. aculeastrum. He further worked and reported on its 
antimicrobial, antioxidant and antiproliferative potentials. However, that study did not 
investigate the possible effect of any form of processing on the efficacy of the plant as well as its 
safety in vivo. 
 
Solanum aculeastrum Dunal commonly known as umthuma or goat bitter-apple belongs to the 
family Solanaceae (Fig 2). This plant is widely distributed in southern Africa (Watt and Breyer-
Brand wijk, 1962). It is a thorny perennial plant that grows up to 2–3 m in height with white 
flowers and lemon shaped berries that become yellow-green when ripe (Wanyonyi et al., 2002). 
The extremely bitter berries and leaves are used for the treatment of various diseases in humans 
and domestic animals (Hutchings et al., 1996). The bitter fruits of S. aculeastrum is used fresh, 
dried, ashed or boiled for the treatment of jigger wounds and gonorrhea (Agnew and Agnew, 
1994), rheumatism as well as ringworm in cattle and horses (Watt and Breyer-Brandwijk, 1962). 
An ethnobotanical survey indicated that the berries are used in the treatment of breast cancer in 
the Eastern Cape Province of South Africa (Koduru et al., 2006c).  
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Figure 2. Solanum aculeastrum. Note both the ripe and unripe fruits. 
 
In the last few years, several researchers have reported the effect of both the crude extracts and 
the isolated compounds of S. aculeastrum in various biological systems, as antitumor, 
antimicrobial, anthelmintic, antioxidant as well as molluscicidal agent (Nfi et al., 1999; 
Wanyonyi et al., 2002; Wanyonyi et al., 2003; Koduru et al., 2006a, b, c, d, e; Koduru et al., 
2007a, b; Steenkamp et al., 2007a, b).  
2.1 Chemistry of the plant 
The main constituents of Solanum aculeastrum which have been implicated in the 
pharmacological activities of this plant are steroidal alkaloids. These include β-solamarine, 
solamargine, solasonine, solasodine, solaculine, tomatine and tomatidine (Drewes and van-
Staden, 1995; Wanyonyi et al., 2002; Koduru et al., 2007a). Steroidal alkaloids have been the 
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target of pharmacological investigations because of their structural similarities with anabolic 
steroids, steroidal hormones and corticosteroids (Gurib-Fakim, 2006).  
 
The leaves and berries of S. aculeastrum have also been found to contain mainly straight- chain 
aliphatic hydrocarbons (Koduru et al., 2006a). These authors reported the isolation of volatile 
compounds such as alkanes (64.5%), phthalic acid (14.9%) and fatty acid esters (7.7%) from the 
berries, while the leaves possessed 17.5% alkanes, 17% aldehydes, 15.2% aromatic 
hydrocarbons, 11.8% phthalic acid, 2.3% methyl salicylate and 6.5% terpenoids. 
2.2  Antimicrobial activity 
The antibacterial activity of the methanol and aqueous extracts of the berries have been studied 
extensively using various methods. Wanyonyi et al., (2003) showed that these extracts were 
moderately active against Staphylococcus aureus, Escherichia coli, pseudomonas aureginosa 
and Bacillus subtilis. Koduru et al., (2006d) reported that while the aqueous extracts of the 
berries were not active against all tested bacteria, the methanol extract inhibited these organisms 
with minimum inhibitory concentrations ranging from 4 to10 mg/ml. However, Steenkamp et al., 
(2007a) observed that the aqueous and methanol extracts of the fruits of S. aculeastrum were not 
active against Staphylococcus epidermis and Staphylococcus aureus. 
 
Koduru et al., (2006d) also studied the effect of the aqueous and methanol extracts of S. 
aculeastrum berries against various fungi. Their results showed that these extracts completely 
inhibited the growth of Aspergillus flavus, Aspergillus niger, Fusarium oxysporum, Penicillium 
notatum at 5 mg/ml, however they were inactive against Candida albicans. Steenkamp et al., 
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(2007b) also reported that the methanol and aqueous extracts of the berries inhibited 5 clinical 
isolates and 1 standard strain of Candida albicans at concentrations ranging from 0.04 to 1.50 
mg/ml and 1.88 to 8.50mg/ml respectively. 
2.3  Molluscicidal activity 
The molluscicidal property of the aqueous and methanol extracts of the berries and the root bark 
against Biomphalaria pfeifferri was determined by Wanyonyi et al., 2002. The aqueous extracts 
of the berries were more potent against the test snails than the root bark. Further studies on the 
activity of four alkaloid-rich fractions obtained from the crude methanolic extract showed 100% 
mortality in all the fractions at concentrations ranging from 20 to 40 ppm (Wanyonyi et al., 
2003). 
2.4  Anthelminthic activity 
Nfi et al., (1999) studied the anthelminthic property of S. aculeastrum along with other plants 
used for ethnoveterinary medicine in Cameroon. The roots and leaves of the S. aculeastrum was 
found to possess 34.4% anthelminthic activity compared with Khaya anthoteca (55.8%) and 
Vernonia amygdalina (52.4%). 
2.5  Antioxidant activity 
Koduru et al., (2006b) examined the effect of the extracts of the berries of Solanum aculeastrum 
on free radicals. While the acetone extract did not demonstrate any significant antioxidant 
activity at the tested concentrations, the aqueous extracts possessed higher activity than the 
methanol extracts. The higher antioxidant activity of the aqueous extract was attributed to the 
substantial amount of polar constituents present in the plant.  
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2.6  Anticancer property 
The antiproliferative activity of the aqueous, methanol and acetone extracts of the leaves and 
berries of S. aculeastrum against HeLa, MCF-7 and HT-29 human cancer cell lines was reported 
by Koduru et al., (2006e). Their study showed that the extracts of the leaves showed no 
anticancer property while the methanol and aqueous extracts of the berries possessed the highest 
antiproliferative activity, with IC50 ranging between 17.1 and 48.5 µg/ml.  
 
The effect of solasodine and tomatidine, steroidal alkaloids isolated from the berries of S. 
aculeastrum were also tested on these human cancer cells (Koduru et al., 2007a). Reports from 
this study indicated that pronounced activity was evident from the combined compounds rather 
than the individual compounds. The IC50 of the combined compounds ranging from 126.9 to 
149.3 µM was not comparable to cisplatin (2.5 µM). Also, the compounds, both individually and 
combined, possessed low apoptotic index (0.3 – 4.2%) when compared to cisplatin (9.6%). 
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Anti- nociceptive and anti-inflammatory activities of the aqueous extract of fresh Solanum 
aculeastrum Dunal. berries in male Wistar rats. 
 
Aboyade Oluwaseyi Mayode, Grierson Donald Scott, Afolayan Anthony Jide*. 
Department of Botany, University of Fort Hare, Alice, South Africa 
Abstract 
The berry of Solanum aculeastrum is used among other remedies, for treating inflammatory-
related ailments in South Africa. The aqueous extract of the fresh berries at 25, 50 and 75 mg/kg 
body weight was evaluated for anti-inflammatory and analgesic effects in rats using histamine 
and carrageenan-induced paw oedema as well as formalin and tail immersion tests. The result of 
the phytochemical screening indicated that the berries possess alkaloids, saponins, phenolics, 
flavonoids, cardenolides and dienolides. Oral administration of the extract to Wistar rats 
significantly reduced the formation of oedema induced by carrageenan and histamine after 3 h. 
The extracts also prolonged the reaction time in the tail immersion-induced pain 60 min after 
administration. In addition, the extract significantly suppressed the nociceptive response in the 
early and late phases of the formalin induced pain in a dose-dependent manner with more 
pronounced effect on the late phase. These results also compared well with those of 
indomethacin, the reference drug used in this study. This study therefore gives credence to the 
traditional uses of Solanum aculeastrum in the treatment of certain conditions associated with 
inflammatory pain. 
 
Key words: Solanum aculeastrum, anti-inflammatory, analgesic. 
*Corresponding author: Fax: +27 86 628 2295 Email: aafolayan@ufh.ac.za. 
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3.1 Introduction 
Inflammation is a process which involves the response of cellular tissues to foreign bodies such 
as pathogenic micro-organisms, toxic chemicals, parasites and injury (van Kempen et al., 2006).   
Several studies have established a role of inflammation in the initiation of diseases such as 
diabetes, rheumatoid arthritis and cancer (Balkwill and Mantovani, 2001; Coussens and Werb, 
2002). Inflammatory-related ailments are treated mainly with non-steroidal anti-inflammatory 
drugs (NSAIDs). These drugs are used to reduce the consequences of inflammation (Vane and 
Botting, 1996). For example, indomethacin has been found to block carcinogenesis in animals by 
reducing the production of inflammatory cytokines (Federico et al., 2007). However, prolonged 
use of these drugs has been reported to produce frequent adverse effects such as dyspepsia and 
severe gastrointestinal complications (Bures et al., 2002). Therefore, there is a need for potent 
drugs with fewer side effects. As a result, the search for other alternatives have become 
necessary.  
Plants possess biologically active compounds of medicinal value (Talhouk et al., 2007). Extracts 
of many plants have been used to treat inflammation-related ailments in the local communities of 
developing countries. Solanum aculeastrum Dunal. (Solanaceae) commonly known as Umthuma 
by the Xhosa speaking people in South Africa is one of such plants. This plant, also known as 
goat bitter apple, is widely distributed in southern Africa (Watt and Breyer-Brand wijk, 1962). It 
is a thorny perennial plant that grows up to 2–3 m in height with white flowers and lemon shaped 
berries that become yellow-green when ripe (Wanyonyi et al., 2002). The bitter fruits of S. 
aculeastrum is used fresh, dried, ashed or boiled for treating jigger wound and gonorrhea 
(Agnew and Agnew, 1994), rheumatism as well as ringworm in cattle and horses (Watt and 
Breyer-Brand wijk, 1962). Pharmacological studies have revealed the antimicrobial and 
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anticancer properties of the leaves and berries (Koduru et al., 2006a, b). Steroidal alkaloids, the 
major components of the berries of S. aculeastrum produced molluscicidal and anticancer effects 
in vitro (Koduru et al., 2007b; Wanyonyi et al., 2002; Drews and Van Staden, 1995).  
The main objective of the present study was to evaluate the anti-inflammatory and anti-
nociceptive potentials of S. aculeastrum berries in animal models since the berry is used for the 
local treatment of some painful inflammatory conditions. 
  
3.2 Materials and methods 
3.2.1 Collection of plant materials and authentication 
Fresh berries of S. aculeastrum collected from Kayalethu village in the Eastern Cape province of 
South Africa, was authenticated by Prof. D.S Grierson at the Department of Botany, University 
of Fort Hare. A voucher specimen (SA/Med 01) was deposited at the Giffens herbarium of the 
University.  
3.2.2 Extraction of plant materials  
The berry (500 g), cut into small pieces, was  extracted in 1000 ml of distilled water for 48 h on a 
mechanical shaker (Stuart Scientific Orbital Shaker SO1, United Kingdom). The extract was 
filtered using a Buchner funnel and Whatman No 1 filter paper. The resulting filtrate was freeze 
dried (Vir Tis benchtop K, Vir Tis Company, Gardiner, NY) to give a yield of 7.50 g. This was 
reconstituted in distilled water to give the required doses for each experiment. 
3.2.3 Animals 
Male rats (Rattus norvegicus) of Wistar strains weighing between 120 and 180 g were 
obtained from the Experimental Animal House of the Agricultural and Rural Development 
Research Institute, University of Fort Hare. The animals were housed in clean metabolic cages 
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placed in well ventilated house with optimum condition (temperature 28 ± 1oC; photoperiod: 12 
h natural light and 12 h dark; humidity: 45-50%). They were also allowed free access to food 
(Balanced Trusty Chunks (Pioneer Foods (Pty) Ltd, Huguenot, South Africa) and water.  All 
experimental protocols were in compliance with University of Fort Hare Ethics Committee on 
Research in Animals as well as internationally accepted principles for laboratory animal use and 
care. 
3.2.4 Chemicals  
Carrageenan, Tween-80, indomethacin and histamine were obtained from Sigma-Aldrich 
Chemie Gmbh, Steinheim, Germany. All other chemicals used were of analytical grade and were 
supplied by Merck Chemicals (Pty) Ltd., Bellville, South Africa.  
3.2.5 Phytochemical screening 
The screening for some chemical constituents of the extract was carried out as described for 
tannins and triterpenes (Odebiyi and Sofowora, 1978), alkaloids (Harbourne, 1973), phenolics 
and flavonoids (Awe and Sodipo, 2001), cardiac glycosides, saponins and steroids (Edeoga et al., 
2005), cardenolides, dienolides and anthraquinones (Trease and Evans, 1989). 
3.2.6 Anti-inflammatory activity 
3.2.6.1  Carrageenan-induced paw oedema 
Thirty rats were grouped into five of six animals each. While the first group served as the 
negative control, the second, third and fourth groups received indomethacin (10 mgkg-1 b.wt) and 
extract at 25, 50 and 75 mgkg-1 body weight respectively. The extract was dissolved in normal 
saline while indomethacin was suspended in 3% Tween 80 in normal saline. Carrageenan 
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solution (0.1 ml of 1%) was injected into the sub plantar region of right hind paw of the rats, 1 h 
after intraperitoneal administration of normal saline, indomethacin and the extract (Moody et al., 
2006). The paw volume was measured at 0.5, 1, 2, 4 and 6 h after administration of drug and 
extract using a micrometer screw gauge (SMC-20326, Sterling Manufacturing Company, 
Ambala Cantt, India). 
The anti-inflammatory effect of the extract was calculated using the expression: anti-
inflammatory activity (%) = (1-D/C) X 100, where D represents the average paw volume after 
extract was administered to the rats and C was the average paw volume of the negative control 
animals. The percentage inhibition of inflammation was calculated from the expression: 
inhibition % = D0-Dt/D0 X 100, where D0 was the average inflammation (hind paw oedema) of 
the control group at a given time; and Dt was the average inflammation of the drug treated (i.e. 
extracts or reference indomethacin) rats at the same time (Gupta et al., 2005, Sawadogo et al., 
2006).   
3.2.6.2  Histamine induced paw oedema 
Using the method of Perianayagam et al., (2006), paw oedema was produced by sub-
plantar administration of 0.1% freshly prepared solution of histamine into the right hind paw of 
the rats. The paw volume was recorded at 0 and 1 h after histamine injection. Different groups of 
the rats were pretreated with extract (25, 50 or 75 mg/kg body weight) or with 2 ml/kg b.wt of 
normal saline (vehicle control) or 10 mg/kg body weight indomethacin (reference drug). These 
were administered intraperitoneally 1 h before eliciting paw oedema. The anti-inflammatory 
activity was calculated as described for carrageenan-induced oedema. 
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3.2.7 Analgesic activity 
3.2.7.1  Tail immersion test 
Acute nociception was assessed using the tail immersion test. This method involves 
immersing extreme 3 cm of the rat tail in a waterbath (Buchi waterbath B480, Buchi 
Switzerland) containing water at a temperature of 55 ± 0.50C. The time the animal’s tail spent in 
the water before reacting to the pain is recorded with a stop watch. Each animal served as its own 
control. The average of the values was recorded as the initial reaction time (Tb). The test groups 
were given the extracts (25, 50 or 75 mg/kg body weight), indomethacin (10 mg/kg b.wt) or 
distilled water. The reaction time (Ta) for the test groups were taken at 30, 60 120, 240 and 360 
min after a latency period of 30 min, following administration of the extract and reference drug 
(Vogel and Vogel, 1997). The percentage analgesic activity was computed from the expression: 
 
Percentage analgesic activity = (Ta- Tb) × 100 
                                                      Tb   
3.2.7.2 Formalin induced pain test 
The formalin induced pain test was carried out according to the procedure described by 
Correa and Calixto, (1993). Briefly, 0.05 ml of 2.5% formalin solution was injected into the sub-
plantar of the right hind paw. The number of times the injected paw was licked was recorded and 
was considered as indicative of pain. The animals were pretreated with normal saline, 
indomethacin and extracts, 30 min before the administration of formalin and the response was 
observed for 30 min. 
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3.2.8 Statistical analysis 
 
Data were expressed as means of four replicates. Statistical difference between the control and 
the treated groups were tested by Student’s t-test. Values were considered statistically significant 
at p < 0.05.  
 
 
3.3 Results  
Phytochemical screening of the aqueous extract of Solanum aculeastrum berries showed 
the presence of alkaloids, saponins, phenolics, flavonoids, cardenolides and dienolides.  
In the carrageenan-induced inflammatory model, oedema was reduced by the aqueous 
extract of S. aculeastrum at concentrations of 25, 50 and 75 mgkg-1 in a dose-dependent manner. 
Maximum inhibition of paw oedema was observed at the end of 6 h (Table 1). The percentage 
reduction in inflammation diameter was highly significant in the group treated with 75 mgkg-1 of 
the extract after 3 h compared to the control.  
The sub-acute inflammation test with histamine showed an inhibition of the paw oedema 
by indomethacin and the extract in a dose-dependent manner, while an increase in paw volume 
of the negative control group was observed. The extract at 75 mgkg-1 body weight and 
indomethacin exhibited comparable activity at 6 h. 
All the doses of the extract (25, 50 and 75 mgkg-1 b.wt), had analgesic effect on both 
early and late phases of the formalin test as shown on Table 3. These phases correspond to 
neurogenic and inflammatory pains respectively. Inhibition of pain resulting from inflammation 
was higher than the neurogenic-induced pain at all concentrations tested. The animals treated 
with the highest dose (75 mgkg-1 b.wt) exhibited more prominent response to the pain at both 
phases compared to indomethacin.  
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Following 30 min latency period, 50 and 75 mgkg-1 of orally administered extract caused 
reduction of the painful sensation due to tail immersion in warm water (Fig. 1). The 
antinociceptive property of the extract at 75 mgkg-1 was more pronounced than that of 
indomethacin at the 60 min time point.  
3.4 Discussion 
The study indicated that the aqueous extract of fresh Solanum aculeastrum berry possess 
both peripheral and central analgesic properties as well as anti-inflammatory property.  
The ability of anti-inflammatory agents to inhibit mediators of acute inflammation is the 
basis of the carrageenan-induced inflammation test. These mediators include histamine, 
serotonin and bradykinnins, which induce the first phase of inflammation (Kasahara et al., 2002). 
The second, late phase of inflammation is induced mainly by prostaglandins which are released 
from the third hour (Di-Rosa et al., 1971). The pronounced anti-inflammatory effect of S. 
aculeastrum berry observed in both the carrageenan and histamine-induced oedema test from 4 h 
is an indication of the potential of the extract to inhibit the release of prostaglandins (Di-Rosa et 
al., 1971). These results indicate the effectiveness of Solanum aculeastrum on acute 
inflammatory conditions.  
Phytochemical screening of the extract shows that the berries possess alkaloids, saponins, 
phenolics, flavonoids, cardenolides and dienolides. Of these, flavonoids are the main compounds 
possessing anti-inflammatory activities (Talhouk et al., 2007). Many studies have also 
demonstrated the anti-inflammatory and analgesic properties of alkaloids, phenols (Ahmadiani et 
al., 2001) and saponins (Peana et al., 1997). The study of Filderman and Kovacs, (1969), showed 
that the oral administration of tomatine, one of the steroidal alkaloids found in Solanum 
aculeastrum, exerted significant dose dependent inhibitory activity on oedema formation. 
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Therefore, it could be suggested that the anti-inflammatory property of the berries of this plant 
may be due to the presence of these active constituents. 
The formalin test is a more valid model for the assessment of clinical pain (Tjolsen et al., 
1992) producing distinct biphasic responses (Vasudevan et al., 2007). Various analgesics differ 
in their response to the formalin test. Drugs such as opioids inhibit both phases of the formalin 
test because they act on the central nervous system (Shibata et al., 1989), while aspirin, 
hydrocortisone and dexamethazone act peripherally, thereby inhibiting only the second phase 
(Vasudevan et al., 2007). The first (neurologic) phase results from the stimulation of nociceptors 
while the second phase is of an inflammatory pain origin. Assessment of the anti-nociceptive 
response using the formalin test showed that all the doses in this study inhibited both phases of 
the formalin test. The highest dose exhibited more prominent response to the pain at both phases 
compared to indomethacin (Table 3). Therefore, the result of this study has suggested that the 
Solanum aculeastrum extract acted centrally and peripherally in the formalin test. 
The study also showed that the extract of this plant possesses centrally acting protective 
effect in the tail immersion test. The result indicated that after 30 min latency period, 50 and 75 
mgkg-1 of orally administered extract caused reduction of the painful sensation by the warm 
water. The protective effect at 75 mgkg-1 b.wt was more pronounced than indomethacin, which 
was inactive.  
 
In conclusion, the anti-inflammatory and analgesic properties of Solanum aculeastrum berry 
observed in these models might, in part, be due to the presence of compounds such as alkaloids, 
saponins, phenolics and flavonoids. The results also suggest a rationale for the traditional uses of 
this plant in southern Africa for some painful inflammatory conditions.  
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Table 1: Effect of oral administration of S. aculeastrum berries on carrageenan-induced paw oedema in Wistar rats (n = 6; X ± S.D) 
      Differences in right hind paw (in mm) 
Treatment Dose (mg/kg)  1 h          2 h        3 h            4 h                 6 h 
____________________________________________________________________________________________________________________________ 
Control    0      0.72 ± 0.08a               2.08 ± 0.03a                    2.36 ± 0.01a      2.18 ± 0.02a                 1.56 ± 0.02a  
SAB   25      0.58 ± 0.09a (11.9)         0.86 ± 0.1 b (49.5)          1.27 ± 0.20c (35.5)         0.90 ± 0.09b (49.2)          0.28 ± 0.06d (77.7) 
50      0.62 ± 0.06a (7.3)           1.00 ± 0.08c (43.0)          0.67 ± 0.09d (63.9)      0.52 ± 0.08d (69.7)          0.26 ± 0.07c (79.7) 
75     0.36 ± 0.04b (46.5)         0.94 ± 0.04d (47.4)          0.93 ± 0.05e (52.8)      0.65 ± 0.07c (63.9)          0.08 ± 0.01e (96.9) 
Indomethacin  10     0.45 ± 0.09a (40.4)         0.80 ± 0.05d (59.6)          1.33 ± 0.30b (42.3)      0.51 ± 0.07e (74.1)          0.29 ± 0.09b (80.2) 
Values carrying superscripts different from the control down the group for each hour are significantly different (P < 0.05) 
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Table 2: Effect of oral administration of S. aculeastrum berries on histamine-induced paw oedema in Wistar rats (n = 6; X  ± S.D) 
      
         Differences in paw volume (mm) 
Treatment Dose (mg/kg)  1 h          2 h        3 h                 4 h             6 h 
____________________________________________________________________________________________________________________________ 
Control    0      0.78 ± 0.06a                0.86 ± 0.06a                     1.03 ± 0.01a                     1.16 ± 0.03a                  1.24 ± 0.11a  
SAB   25      0.71 ± 0.06a (5.1)           0.72 ± 0.05b (12.2)          0.65 ± 0.09b (31.5)          0.48 ± 0.10b (53.2)         0.33 ± 0.09b (69.4) 
50      0.69 ± 0.17a (9.9)           0.73 ± 0.11a (12.3)          0.34 ± 0.08c (63.5)          0.35 ± 0.07d (66.3)         0.35 ± 0.09c (73.1) 
75      0.55 ± 0.07a (26.9)         0.40 ± 0.07c (49.8)          0.39 ± 0.07c (58.0)          0.16 ± 0.09d (84.1)         0.12 ± 0.04d (92.0) 
Indomethacin  10      0.54 ± 0.09a (19.2)        0.51 ± 0.07b (29.7)           0.28 ± 0.08d (66.8)          0.20 ± 0.09c (77.8)         0.14 ± 0.08d (86.0) 
 
Values carrying superscripts different from the control down the group for each hour are significantly different (P < 0.05) 
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Table 3: Effect of oral administration of Solanum aculeastrum berries on formalin nociception 
response in Wistar rats (n = 6; X  ± S.D) 
     Number of times licked (mean ± SD) 
             _________________________________________________ 
Treatment    Dose (mgkg-1)       Phase 1        % Inhibition   Phase 2 % Inhibition 
Control  0          14.00 ± 1.41a       -           32.25 ± 8.42a         - 
Extract   25          10.67 ± 3.21a    23.8           15.50 ± 7.78a       51.9  
   50            6.00 ± 1.63b        57.1             5.67 ± 2.31c       82.4  
   75           5.00 ± 1.41c          64.3  4.00 ± 2.65c       87.6 
Indomethacin  10           5.25 ± 1.71b          62.5  8.00 ± 2.16b       75.2 
Values carrying superscripts different from the control down the group for each hour are 
significantly different (P < 0.05) 
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Figure 1: Effect of oral administration of S. aculeastrum berries on tail immersion nociception 
response in male Wistar rats (n = 6; X  ± S.D) 
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Comparative studies on the anti-inflammatory and analgesic activity of the aqueous 
extracts from fresh, dried and boiled berries of Solanum aculeastrum Dunal. 
OM Aboyade, DS Grierson and AJ Afolayan*. 
Department of Botany, University of Fort Hare, Alice, South Africa 
Abstract 
The berry of Solanum aculeastrum Dunal. is used for treating diseases such as rheumatism, 
gonorrhea, breast cancer and other inflammatory-related ailments in South Africa. The aqueous 
extracts of the fresh, dried and boiled berries at doses of 1 and 10 mg/kg body weight was 
evaluated for anti-inflammatory and analgesic effects in male Wistar rats using carrageenan-
induced paw oedema as well as formalin, acetic acid induced writhing and tail immersion tests. 
Oral administration of the extract showed some inhibition of the paw oedema that was not dose 
dependent. The percentage reduction in inflammation diameter was more prominent in both 
concentrations of the boiled fresh berries than indomethacin. The extracts at 10 mg/kg prolonged 
the reaction time in the tail immersion-induced pain 60 min after administration. Although, only 
the extracts of the boiled dried berries (10 mg/kg) suppressed pain in the formalin test at the late 
phase, a more pronounced effect of all the extracts in a dose-dependent manner was observed in 
the late phase than the early phase. The results of the acetic acid induced writhing test showed 
that all the extracts possessed analgesic effect at the tested doses (1 and 10 mg/ml). In 
conclusion, the extracts of Solanum aculeastrum berry did not show considerable anti-
inflammatory and analgesic effects in comparison to indomethacin.  This observation in these 
models might in part be due to the low doses fed to the rats in this experiment. 
Key words: Solanum aculeastrum, anti-inflammatory, analgesic. 
*Corresponding author: Fax: +27 86 628 2295 Email: aafolayan@ufh.ac.za. 
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1.0 Introduction 
Inflammation is the way the body deals with infections and tissue damage (Simmons, 2006).  
Uncontrolled, inflammation can lead to a cascade of diseases such as rheumatoid arthritis, 
chronic asthma, psoriasis, cancer, multiple sclerosis and a host of other diseases (Balkwill and 
Mantovani, 2001; Coussens and Werb, 2002; Simmons, 2006). Various studies have shown that 
inflammation may be an initiator of carcinogenesis via genotoxic and cytotoxic effects (Platz and 
De Marzo, 2004). The longer inflammation persists, the higher the risk of cancer (Federico et al., 
2007). Cancers of infectious etiology such as stomach, bladder, colon, liver and bile duct have 
been linked to inflammation (Coussens and Werb, 2002). Non-steroidal anti-inflammatory drugs 
(NSAIDs) are the main drugs used to reduce the consequences of inflammation (Vane and 
Botting, 1996). Indomethacin, an NSAID, for example has been found to block carcinogenesis in 
animals by reducing the production of inflammatory cytokines (Federico et al., 2007). A lower 
risk of cancer incidence has also been found in people regularly taking NSAIDs (Fosslien, 2000). 
Although, these drugs have been found to be effective, prolonged use has been reported to 
produce frequent adverse effects such as dyspepsia and severe gastrointestinal complications 
(Bures et al., 2002). This has therefore led to various researches to for other effective drugs with 
less/no side effects.  
 
Medicinal plants have been in use since ancient time in the treatment of various ailments. Plants 
such as Catharanthus roseus, Digitalis purpurea, Rauwolfia serpentina, Willow (Salix species), 
Physostigma venenosum have been used for centuries for the treatment of diseases. Since then, 
plants have served as sources of biologically active natural products which are either used as 
commercial drugs or as lead structures for the development of modified derivatives (Cordell et 
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al., 1991). Extracts of Solanum aculeastrum Dunal. (Solanaceae) have been used to treat 
inflammation-related ailments in the local communities of South Africa. This plant also known 
as goat bitter apple is traditionally used by the Xhosa speaking people of South Africa in the 
treatment of breast cancer (Koduru et al., 2007a). S. aculeastrum is widely distributed in 
southern Africa (Watt and Breyer-Brand wijk, 1962) and  the bitter fruits are either used fresh, 
dried, ashed or boiled for treating jigger wound and gonorrhea (Agnew and Agnew, 1994), 
rheumatism as well as ringworm in cattle and horses (Watt and Breyer-Brand wijk, 1962). 
Pharmacological studies have revealed the antimicrobial and anticancer properties of the leaves 
and berries (Koduru et al., 2006a, b).  
 
Previously, the authors studied the anti-inflammatory and analgesic effect of the fresh berries of 
Solanum aculeastrum. Although the extract was found to be active at the tested doses, 
toxicological studies indicated that those concentrations were not completely safe for use. 
Therefore, the main objective of the present study was to compare the anti-inflammatory and 
anti-nociceptive potentials of the fresh and boiled extracts of the berries in animal models in 
view of its use in the local treatment of some painful inflammatory conditions. 
 
2.0 Materials and methods 
2.1 Collection of plant materials and authentication 
Fresh berries collected from Kayalethu village in the Eastern Cape province of South Africa, was 
authenticated by Prof. D.S Grierson at the Department of Botany, University of Fort Hare. A 
voucher specimen (SA/Med 01) deposited at the Giffens Herbarium of the University.  
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2.2 Extraction of plant materials  
The fresh berries collected were washed, cut into pieces and divided into two portions. The first 
portion was oven dried at 40oC , a part of which (400 g) was boiled with distilled water (BDB) 
and the other (300 g) soaked with water (DB) by shaking for 24 h on an orbital shaker. The 
second portion of fresh berries (1500 g) was soaked (FB) and boiled (2000 g) separately with 
distilled water (BFB). The extracts were filtered using a Buchner funnel and Whatman No 1 
filter paper. The filtrates were freeze dried (Vir Tis benchtop K, Vir Tis Company, Gardiner, 
NY) to give yields of 2.03 g (BFB), 2.01 g (FB), 11.85 g (BDB), 13.16 g (DB) per 100g of plant 
material. The crude extracts were then reconstituted in distilled water to give the required doses 
for each experiment. 
2.3 Animals 
Male rats (Rattus norvegicus) of Wistar strains weighing between 120 and 180 g were obtained 
at the Experimental Animal House of the Agricultural and Rural Development Research Institute 
(ARDRI), University of Fort Hare. The animals were housed in clean metabolic cages placed in 
well ventilated house with optimum condition (temperature 28 ± 1oC; photoperiod: 12 h natural 
light and 12 h dark; humidity: 45-50%). They were also allowed free access to food (Balanced 
Trusty Chunks (Pioneer Foods (Pty) Ltd, Huguenot, South Africa) and water.  All experimental 
protocols were in compliance with University of Fort Hare Ethics Committee on Research in 
Animals as well as internationally accepted principles for laboratory animal use and care. 
 
2.4 Chemicals  
Carrageenan, Tween-80, indomethacin and histamine were obtained from Sigma-Aldrich Chemie 
Gmbh, Steinheim, Germany. All other chemicals used were of analytical grade and were 
supplied by Merck Chemicals (Pty) Ltd., Bellville, South Africa.  
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2.5 Anti-inflammatory activity 
2.5.1 Carrageenan-induced paw oedema 
The animals were assigned into ten groups (A-J), each consisting of six rats. Group A (control) 
received only 0.5 ml of normal saline (the vehicle), group B received indomethacin (10 mg/kg) 
while groups C to J were treated with the same volume of the extract preparation corresponding 
to 1 and 10 mg/kg body weight of the extracts respectively. The extracts were dissolved in 
normal saline while indomethacin was suspended in 3% Tween 80 in normal saline. Carrageenan 
solution (0.1 ml of 1%) was injected into the sub plantar region of right hind paw of the rats, 1 h 
after intraperitoneal administration of normal saline, indomethacin or the extract (Moody et al., 
2006). The paw volume was measured at 1, 3 and 5 h after administration of drug and extract 
using a micrometer screw gauge (SMC-20326, Sterling Manufacturing Company, Ambala Cantt, 
India). 
The anti-inflammatory effect of the extract was calculated using the expression: anti-
inflammatory activity (%) = (1-D/C) X 100, where D represents the average paw volume after 
extract was administered to the rats and C was the average paw volume of the negative control 
animals. The percentage inhibition of inflammation was calculated from the expression: % 
inhibition = D0-Dt/D0 X 100, where D0 was the average inflammation (hind paw oedema) of the 
control group at a given time; and Dt was the average inflammation of the drug treated (i.e. 
extracts or reference indomethacin) rats at the same time (Gupta et al., 2005, Sawadogo et al., 
2006).   
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2.6 Analgesic activity 
2.6.1  Tail immersion test 
Acute nociception was assessed using the tail immersion test described by Vogel and Vogel 
(1997). Briefly, this method entails immersing the extreme 3 cm of the rat’s tail in a water bath 
(Buchi water bath B-480, Buchi, Switzerland) maintained at a temperature of 55.00 ± 0.5°C. The 
time spent by the animal before reacting to the pain was measured with a stop watch as the initial 
reaction time (Tb). The various groups of the animals were orally administered with the extracts 
(25, 50 and 75 mg/kg body weight), indomethacin (10 mg/kg body weight) and distilled water. 
The response latency between the onset of immersion and the withdrawal of the tail (Ta) 
following the administration of the extract and the reference drug was recorded at 30, 60 120, 
240 and 360 min after a latency period of 30 min. The percentage analgesic activity was 
computed from the expression: 
Percentage analgesic activity = (Ta – Tb/Tb) x 100 
 
2.6.2  Formalin induced pain test 
The formalin induced pain test was carried out according to the procedure as described by Correa 
and Calixto, (1993). Briefly, 0.05 ml of 2.5% formalin solution was injected into the sub-plantar 
of the right hind paw. The number of times the rat licked the injected paw was recorded and was 
considered as indicative of pain. The animals were pretreated with normal saline, indomethacin 
and extracts, 30 min before the administration of formalin, and the responses were observed for 
30 min. 
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2.7 Statistical analysis. 
Data were expressed as mean of six replicates and were subjected to one way analysis of 
variance (ANOVA). Means were separated by the Duncan multiple range test using SAS and 
complemented with student’s t-test. Values were considered statistically significant at p < 0.05. 
 
3.0 Results 
The sub-acute inflammation test with the carrageenan-induced inflammatory model showed that 
the inhibition of the paw oedema by all the extracts was not dose dependent (Table 1). The 
percentage reduction in inflammation diameter was highly significant (p < 0.05) and more 
prominent in both concentrations of the boiled fresh berries than indomethacin. At 1 and 5 h (1 
mg/kg) for dried berry and 5 h (1 and 10 mg/kg) fresh berry, significant reduction in the 
inflammation diameter of the rats treated with these extracts was achieved.   
 
Regarding the inhibition of pain in the formalin nociception test, all the extracts at 1 mg/ml did 
not reduce pain to a significant level compared to the control (Table 2). The boiled dried berry 
extract showed analgesic effect in both the early and late phase of the test, while the extracts of 
the dried, fresh and boiled fresh berries failed to demonstrate any significant analgesic effect. 
Inhibition of pain resulting from inflammation was higher in all the animals compared to the 
neurogenic induced pain.  
 
The 30 min latency period following the oral administration of the aqueous extracts of the dried, 
fresh, boiled dried and boiled fresh extracts of the berry showed that the extracts and 
indomethacin at 10 mg/kg significantly increased the reaction time. Indomethacin and the extract 
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of the boiled dried berries at 10 mg/kg showed their maximal analgesic effect at 1 h post-
treatment with percentage inhibitions of 28.04 and 25.11 % respectively. At 1 mg/kg, only the 
animals fed with the boiled extracts of the fresh berries demonstrated any significant effect on 
pain (24.08%) in the tail immersion test at the fifth hour (Table 3).  
 
4.0 Discussion 
 
The results of the present study showed the effect of processing on the activity of the aqueous 
extracts of Solanum aculeastrum berries. The four extracts varied in their potential to act either 
centrally or peripherally in their effect on pain. The peripheral analgesic activity of this plant can 
be deduced from its inhibitory effect on chemically induced nociceptive stimuli. Only the boiled 
extracts of the dried and fresh berries exhibited both peripheral and centrally mediated protective 
effect on the animals.   
 
Assessment of the analgesic response using the formalin test showed that at both concentrations 
tested, none of the extracts inhibited the phase of the formalin test which produces a biphasic 
response in agreement with the observations of Vasudevan et al., 2007. The study showed the 
extracts exerted significant effect in the second phase (resulting from an inflammatory pain) than 
in the first phase (caused by the stimulation of nociceptors) of the formalin test corroborating the 
studies of Coderre and Melzack, 1992 and Abbadie et al., 1997. Also boiling had differing 
effects on the activity of the fresh and dried extracts. While inhibition of pain increased when the 
dried extracts were boiled, the opposite trend was observed with the boiled, fresh extracts. 
Conversely, the tail immersion test showed that boiling had similar, positive effects on the 
inhibitory performance of both fresh and dry extracts. 
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The carrageenan induced oedema results from the ability of anti-inflammatory agents to inhibit 
mediators of acute inflammation. This study showed that the effect of the extracts on this model 
was not dose dependent. At 10 mg/kg, extracts of the dried, boiled dried and boiled fresh berries 
possessed higher inhibitory activity than the fresh extracts at all the measurement intervals. This 
implies that processing enhanced the anti-inflammatory potential of the berries of S. 
aculeastrum. 
 
In conclusion, the extracts of Solanum aculeastrum berry did show comparable anti-
inflammatory and analgesic effects to indomethacin.  Also, in all but the formalin test, 
processing improved anti-inflammatory and analgesic activity of the berry extracts.  
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Table 1: Effect of aqueous extract of Solanum aculeastrum berries and indomethacin on carrageenan-induced edema paws volume in 
 
 male Wistar rats. n = 6, X  ± SD 
 
___________________________________________________________________________________________________________ 
  Treatment Doses       Right hind paw volume (mm)  
  Groups (mg/kg body weight) _____________________________________________________________________________  
1 h                        3 h                         5 h                       
___________________________________________________________________________________________________________ 
 
Control  0   1.26 ± 0.28a   1.83 ± 0.56a   1.85 ± 0.50a 
 
Indomethacin  10   0.53 ± 0.09a (58.3)  0.65 ± 0.09ba (62.6)  0.55 ± 0.02ba (68.8) 
 
Dried berries  1   0.22 ± 0.67b (80.3)  1.03 ± 0.61bcd (39.5)  0.19 ± 0.13c (87.8) 
 
   10   0.49 ± 0.23b (56.4)  0.76 ± 0.25c (52.2)  0.73 ± 0.04c (54.6) 
 
Boiled dried berries 1   0.59 ± 0.55b (45.3)  1.17 ± 0.17bc (25.7)  0.52 ± 0.18c (64.8) 
 
   10   0.55 ± 0.12b (50.4)  0.78 ± 0.17c (49.6)  0.47 ± 0.09dc (68.8) 
 
Fresh berries  1   0.49 ± 0b (55.3)  0.84 ± 0.33cd (46.2)  0.39 ± 0.21c (74.0) 
 
   10   0.73 ± 0.30b (37.2)  1.00 ± 0.40bc (39.1)  0.31 ± 0.20dc (79.4) 
 
Boiled fresh berries 1   0.44 ± 0.31b (60.5)  0.65 ± 0.32d (86.1)  0.73 ± 0.42cb (95.2) 
 
   10   0.58 ± 0.06b (53.2)  0.56 ± 0.08c (66.9)  0.07 ± 0.13d (95.9) 
____________________________________________________________________________________________________________ 
 
Values in brackets denote percentage inhibition of the edema paw volume. 
a-d
 Values carrying superscripts indicate difference (P<0.05). 
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Table 2: Effect of oral administration of Solanum aculeastrum berries on formalin nociception 
response in rats (n = 6), X  ± SD 
     Number of times licked (mean ± SD) 
             _________________________________________________ 
Treatment    Dose (mgkg-1)       Phase 1        % Inhibition   Phase 2 % Inhibition 
Control  0          16.0 ± 4.00a       -           28.3 ± 7.64a         - 
Dried berries  1          19.0 ± 5.57a    -18.8           21.3 ± 3.21ba       24.7 
   10          16.3 ± 2.52ba    -2.08           20.3 ± 0.58ba       28.2   
Boiled dried berries 1          14.3 ± 8.08a            10.4          14.0 ± 7.81b       50.6 
   10            9.0 ± 1.73bc          43.8         12.7 ± 2.52b       55.3  
Fresh berries  1           17.3 ± 1.53a            -8.3          19.0 ± 1.73b       32.9 
   10           15.3 ± 3.21ba       4.2          17.3 ± 0.58b       38.8 
Boiled fresh berries 1          20.0 ± 1.0a    -25.0          22.3 ± 1.53ba       21.2 
   10          20.3 ± 8.96ba    -27.1          21.0 ± 9.64ba       25.9 
Indomethacin  10            3.0 ± 1.0b              81.3            1.7 ± 0.58c       94.1 
a-c
 Values carrying superscripts indicate difference (P<0.05). 
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Table 3: Effect of oral administration of aqueous extracts of S. aculeastrum berries on tail immersion nociception response in rats  
              (n = 6), X  ± SD. 
___________________________________________________________________________________________________________ 
  Treatment Doses         
  Groups (mg/kg body weight)  0 h       1 h                           3 h                                5 h                       
_____________________________________________________________________________  
 Time (sec) 
___________________________________________________________________________________________________________ 
  
Control  0  2.83 ± 0.45a  3.77 ± 1.17a        4.08 ± 1.76a           2.88 ± 0.50a 
 
Indomethacin  10  2.28 ± 0.49ba  2.92 ± 1.07ba (28.04)       2.50 ± 0.39b (9.96)          2.51 ± 0.31ba (10.32) 
 
Dried berries  1  2.98 ± 1.01a  2.22 ± 0.42bc (-25.42)       1.99 ± 0.70b (-33.03)       2.57 ± 0.72ba (-13.55) 
 
   10  2.47 ± 0.56a  2.50 ± 0.75bc (1.28)       1.92 ± 0.41b (-22.08)       2.71 ± 0.55a (9.86) 
 
Boiled dried berries 1  2.44 ± 0.47a  2.30 ± 0.49bc (-5.73)       1.60 ± 0.18b (-34.40)       1.98 ± 0.11bc (-18.84) 
 
   10  2.22 ± 0.38a  2.77 ± 0.19b (25.11)       2.60 ± 0.28ba (17.22)       2.40 ± 0.26ba (8.4) 
 
Fresh berries  1  2.00 ± 0.17a  1.73 ± 0.24bc (-13.73)       1.51 ± 0.12b (-24.46)       1.35 ± 0.11c (-32.61) 
 
   10  2.56 ± 0.22a  2.66 ± 0.56b (3.98)       2.53 ± 0.36ba (-1.17)        2.66 ± 0.89ba (3.85) 
 
Boiled fresh berries 1  1.30 ± 0.08b  1.18 ± 0.04c (-8.74)       1.38 ± 0.02b (6.78)           1.61 ± 0.13c (24.08) 
 
   10  2.16 ± 0.04a  2.30 ± 0.03b (6.41)       2.33 ± 0.03ba (7.96)          2.44 ± 0.03ba (13.21) 
____________________________________________________________________________________________________________  
 
Percentages of protection against thermally induced pain by warm water are in parentheses. 
a-c
 Values carrying superscripts indicate difference (P<0.05). 
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Non specific cytotoxicity of Solanum aculeastrum berries on cancerous 
and non-cancerous cells 
OM Aboyade1, DS Grierson1, M van de Venter2, D du Plessis-Stoman2 and AJ Afolayan1* 
1Department of Botany, University of Fort Hare, Alice 5700, South Africa 
2Department of Biochemistry and Microbiology, Nelson Mandela Metropolitan University, Port 
Elizabeth 6031, South Africa 
Abstract 
Ethnobotanical studies conducted on Solanum aculeastrum Dunal (Solanaceae), have 
shown that extracts of the berry are used for the treatment of breast cancer. This claim 
has been validated by scientific studies. As part of our on going research, we compared 
the cytotoxic effect of the cold aqueous extracts of the fresh, dried, and also the boiled 
extracts of the fresh and dried berries on human cancer cells and non-cancerous liver 
cells. The extracts obtained from the berries were studied against HeLa, MCF-7, HT-29, 
and U973 human cancer cells and non-cancerous Chang liver cells using the MTT assay. 
Annexin V-FITC/PI assay was conducted to confirm apoptosis. The present results 
demonstrated that all the extracts of S. aculeastrum are potent inhibitors of human breast, 
cervical, and colonic carcinoma cells. In terms of relative potency, the cold fresh berries 
appeared to be the most active of the extracts, especially at low concentrations. However, 
not only did the extracts inhibit the growth of the cancer cells, but they were also 
cytotoxic against non-cancerous cells (both the actively dividing and confluent Chang 
liver cells). The observed cytotoxic effect of the extracts was confirmed by the Annexin 
V-FITC/PI test, where the extracts caused more necrosis than apoptosis in the U973 cells. 
For the boiled extracts, necrotic ratio decreased (See Table 2). 
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The lack of differential effect of S. aculeastrum extracts on cancerous and non-cancerous 
cells implies that in addition to efficacy, safety considerations should govern possible 
therapeutic uses of the extracts of the berries of this plant. 
Key words: Apoptosis, cytotoxicity, MTT assay, Solanum aculeastrum. 
*Corresponding author: Phone number: + 27 82 202 2167, Postal address: P. O. Box 95, 
Alice 5700, South Africa, Fax: +27 86 628 2295, Email: aafolayan@ufh.ac.za.  
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1.0 Introduction 
Biologically active products from plants have been sources of new therapeutic 
agents for cancer treatment (Hartwell, 1982). These products have served either as 
commercial drugs or as lead structures for the development of modified derivatives 
possessing enhanced activity (Cordell et al., 1991). Research is ongoing to discover more 
natural sources of drugs for the treatment of cancer. The increase in the awareness and 
utilization of these drugs in the treatment of cancer has been due to the non-reliability and 
indefinitive cure by conventional medicines. One means of drug discovery has been the 
collection of information on the plants used in the treatment of cancer by different 
communities all over the world. 
In Africa, herbal medicines are often used as treatment for cancer and for 
conditions often referred to as cancer such as warts, tumors, polyps, abscesses, calluses 
and hard swellings (Cragg and Newman, 2005). These herbal medicines are prepared 
either by drying, boiling or ashing of plant materials to increase their biological activity. 
Various reports exist on the increased biological properties resulting from steam 
processing of medicinal plants (Jung and Jin, 1996; Kim et al., 1999; Yoo et al., 2007). 
Therefore, in our study on Solanum aculeastrum Dunal (Solanaceae), a plant widely used 
in South Africa in the treatment of various diseases in humans and domestic animals 
(Hutchings et al., 1996), the effect of boiling of the fresh and dried berries on cytotoxicity 
was investigated.  The extract of the boiled berries of S. aculeastrum is used in the 
treatment of jigger wounds, gonorrhoea (Agnew and Agnew, 1994), rheumatism, and 
ringworm in cattle and horses (Watt and Breyer-Brandwijk, 1962). An ethnobotanical 
report by Koduru et al., (2006b) showed that the aqueous extracts of the boiled berries of 
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S. aculeastrum are used in the treatment of breast cancer. Studies conducted by the same 
author reported that the cold aqueous extracts of the dried berries and leaves, and 
steroidal alkaloids isolated from S. aculeastrum, showed significant activity against 
HeLa, MCF-7, and HT-29 cancer cell lines (Koduru et al., 2006a, 2007).  
In this study, in addition to the investigation of the cytotoxic effects of the cold 
and boiled extracts, the selective cytotoxicity of the extracts against the MCF-7, HT-29, 
U973 cancer cell lines and non-cancerous Chang liver cells was determined.  
2.0 Materials and methods 
2.1 Plant Material 
Fresh berries of Solanum aculeastrum were collected from Kayalethu village in 
the Eastern Cape province of South Africa in December 2008. The fruit was 
authenticated by Prof. D.S Grierson at the Department of Botany, University of Fort Hare 
and a voucher specimen (SA/Med 01) deposited at the Giffens herbarium. 
2.2 Preparation of Extracts 
The fresh berries collected were washed, cut into pieces and divided into two 
portions. The first portion was oven dried at 40°C , a part of which (400 g) was boiled in 
distilled water (BDB) and the other (300 g) soaked in cold water (DB) by shaking for 24 
h on an orbital shaker. The second portion of the fresh berries was also divided into two 
parts, one part (1500 g) was soaked in cold water (FB) and the other (2000 g) boiled 
separately with distilled water (BFB). The extracts were filtered using a Buchner funnel 
and Whatman No 1 filter paper, then freeze dried (Vir Tis benchtop K, Vir Tis Company, 
Gardiner, NY) to give yields of 11.85 g (BDB), 13.16 g (DB) per 100 g of dry plant 
material, 2.03 g (BFB), 2.01 g (FB) per 100 g of fresh plant material.  
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2.3 Human Carcinoma cell lines and culture medium 
HT-29 (colonic adenocarcinoma), HeLa (cervical carcinoma), MCF-7 (breast 
adenocarcinoma) and Chang liver cells (originally isolated in 1954 from a normal human 
liver by RS Chang from Harvard School of Public Health, Boston, MA) were cultured in 
10 cm culture dishes in growth medium [antibiotic-free RPMI 1640 medium, (Sigma, 
Germany) containing 10% heat inactivated fetal bovine serum (Highveld Biological, 
South Africa), 25 mM HEPES and 2 mM glutamine] in a humidified 5% CO2 incubator 
at 37°C. HT-29, HeLa, MCF-7 and Chang liver cells were obtained from the American 
Type Culture Collection (ATCC), USA and U937 cell lines from Highveld Biological, 
South Africa. 
2.4 In vitro Cytotoxic Assay 
The cells (200 µL aliquots) were seeded into 96-well culture plates (Nunclon, 
Roskilde, Denmark) at a density of 6000 cells/well to determine their viability. Cells 
were allowed to attach for 24 h in a humidified 5% CO2 incubator at 37°C. The cold 
aqueous extracts of the fresh and dried and boiled aqueous extracts of the fresh and dried 
berries were solubilized in DMSO before further dilution with growth medium. The final 
DMSO concentration in culture wells never exceeded 0.5%.  Cisplatin was used as a 
positive control at concentrations of 10 and 100 µM. Cells were exposed to the extracts 
and cisplatin for 48 h. Immediately following the 48 h incubation period, cell numbers 
were determined using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyl tetrazolium 
bromide) assay as previously described by Alley et al., (1988) and Brauns et al., (2004). 
The cells were incubated with 200 µL MTT (Sigma) (0.5 mg/mL in growth medium) for 
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3 h at 37°C. The formazan product was then dissolved in DMSO and plates were agitated 
on a shaker for 5 min, before the absorbance was read at 540 nm on multiwell scanning 
spectrophotometer (Multiskan MS, Labsystems). The values obtained were used to 
determine the percentage inhibition of cell growth caused by the extracts (Hagopian et 
al., 1999; Huq et al., 2004). 
2.5 Annexin V-FITC/PI 
U937 cells (1.0 × 106 cells/mL) were seeded in growth medium and 10 µM 
cisplatin and 15.6 µg/mL of DB, BDB, FB and BFB respectively were added to the test 
flasks. The cells were incubated for 24 h before the Annexin V-FITC Apoptosis detection 
kit (Beckman Coulter, Fullerton, CA, USA) was used to distinguish between apoptotic 
and necrotic cells. The reagents were prepared as per kit instructions. The cells were 
collected and centrifuged for 5 min at 500 × g at 4°C. The supernatant was discarded and 
the pellet re-suspended in ice-cold 1X binding buffer to make 2.0 × 106 cells/mL 
suspension. The tubes were kept on ice. To 100 µL of the cell suspension, 1 µL of 
Annexin V-FITC solution and 5 µL of dissolved propidium iodide (PI) were added and 
mixed gently. The tubes were incubated for 15 min on ice and in the dark before 400 µL 
of ice-cold 1X binding buffer was added. The samples were analyzed on a Beckman 
Coulter FC500 flow cytometer. A minimum of 10,000 events were acquired per sample. 
2.6 Cell cycle analysis 
The cell suspensions prepared for Annexin V-FITC/PI staining were also used for 
cell cycle analysis. Cells were fixed and stained using the Coulter DNA Prep Reagents kit 
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(Beckman Coulter). The cells were analyzed on a Beckman Coulter FC500 flow 
cytometer.  A minimum of 10,000 events were acquired per sample. 
2.7 Statistical analysis 
Screening for cytotoxicity and log dose-dependent responses were performed in 
triplicate and quadruplicates respectively. The results were expressed as percentage 
growth inhibition of control. The treatment values were compared to control values using 
the two-sample student t-test. IC50 values for growth inhibition was derived from a 
nonlinear regression model (curve fit) based on sigmoidal dose response curve (variable) 
and computed using GraphPadPrism version 4 (GraphPad). 
3.0 Results 
3.1 In vitro cytotoxic assay 
The relative cytotoxic activity of the cold extracts of the fresh and dried and the 
boiled aqueous extracts of fresh and dried berries of Solanum aculeastrum on human 
tumor cells was measured by means of MTT assay in the MCF-7, HT-29 and HeLa 
cancer cell lines. The growth inhibition of the extracts against the cancer and non-
cancerous cell lines is depicted in Figure 1. All the extracts inhibited the cancer cell lines, 
with the best activity observed in the breast cancer (MCF-7) cell line. Table 1 represents 
the IC50 values of extracts on the cell lines. All the extracts showed cytotoxic effect on all 
the cancer cells with the cold fresh berries possessing the lowest IC50 values across the 
cancer cells.  
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3.2 Growth Inhibition of non-malignant Chang human liver (Chang) 
To assess whether the extracts demonstrated toxicity in non-cancerous cells, 
Chang liver cells were plated at a density of 6000 cells/well and also to confluence. These 
cells were then cultured in the presence of varying concentrations of the extracts for 48 h. 
Table 1 shows that these extracts also inhibited the growth of these cells. Interestingly, 
the cold extract of the fresh berries also showed the lowest IC 50 values in both the Chang 
and confluent Chang liver cells.  
3.3 Annexin V-FITC/PI 
To investigate the effect of FB, DB, BFB and BDB on the induction of apoptosis 
in U937 cells, Annexin V-FITC/PI staining and flow cytometric measurements were used 
to quantify the percentage of apoptosis in the total cell population. As shown in Table 2, 
after incubation with the extracts at a concentration of 15.6 µg/ml and cisplatin at 10 µM 
for 24 h, the percentage of necrotic cells were more than the early apoptotic cells in all 
the treatments. However, on boiling of the fresh and dried berries, the percentage of 
viable and early apoptotic cells increased while necrotic cells decreased. 
4.0 Discussion 
  A number of the currently cytotoxic chemotherapeutic drugs in use as systemic 
therapy have been designed not only to specifically kill or inhibit cancer cells but any 
rapidly dividing cell (Lind, 2004). These results from the inability of the 
chemotherapeutic drugs to differentiate between normal and malignant cells, 
consequently causing damage to rapidly regenerating tissues such as bone marrow, hair, 
GIT cells, and resulting in side effects such as hair loss, gastro-intestinal disturbances, 
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myelosuppression etc. (Corrie, 2008).  The problems associated with these drugs have led 
to the intensive search for naturally occurring products with anticancer potentials. This 
has led invariably to an increase in the use of traditional medicines for cancer treatments, 
even though only a few peer-reviewed reports are available regarding their efficacy, 
active principles, mode of action, side effects and possible adverse drug interactions 
(Cuzzolin et al., 2006). 
Solanum aculeastrum berries have been reported to be used in the treatment of 
breast cancer in the Eastern Cape Province of South Africa (Koduru et al., 2006b), and 
previous studies have demonstrated that the extracts and chemical constituents of the 
berries possess cytotoxic activity against estrogen receptor positive human breast 
carcinoma cells (MCF-7), cervical (HeLa) and colonic cancer (HT-29) cells, by the 
induction of cell cycle arrest and apoptosis (Koduru et al., 2006a; 2007). Therefore, as 
part of our on going research of this plant, we compared the cytotoxic effect of the cold 
extracts as well as the boiled extracts of the fresh and dried berries of Solanum 
aculeastrum on HeLa, MCF-7, HT-29 and Chang liver cells. Furthermore, we also 
determined whether these extracts possessed selective cytotoxicity against the 
investigated cancer cells. 
The present results demonstrated that all the extracts of Solanum aculeastrum 
tested are potent inhibitors of human breast, cervical and colonic carcinoma cells. In 
terms of relative potency, the cold fresh berry extracts appeared to be the most active of 
the extracts, especially at low concentrations. However, not only did these extracts inhibit 
the growth of the cancer cells, but they were also cytotoxic against non-cancerous cells 
(both the actively dividing and confluent Chang liver cells). The lack of differential effect 
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of S. aculeastrum extracts on cancerous and non-cancerous cells implies that in addition 
to efficacy, safety considerations should govern possible therapeutic uses of these plant 
extracts (Lee et al., 2004). The indiscriminate increase in the use of extracts of plants 
without recourse to their safety and adverse effects is worrisome because they are 
considered natural (Gesler, 1992). Several reports of side effects after administration of 
traditional medicines have been reported worldwide (Niggemann and Grüber, 2003; Stout 
et al., 2003). A key question for the possible use of the S. aculeastrum extracts evaluated 
in this study in cancer treatment should take into consideration the ratio of the effective 
therapeutic to toxic dose. However, it is worth mentioning that solasodine and 
tomatidine, compounds found in Solanum aculeastrum, have been found to possess 
significant cytotoxic activity against various cancer cell lines (Cham, 1994; Lee et al., 
2004). 
Annexin V-FITC/PI staining was used as a quantitative marker to estimate 
whether the extracts induced cell apoptosis. Apoptosis is a regulated cell death process 
characterized by morphological and biochemical features occurring at different stages. 
One of the earliest signs of an apoptotic cell is the loss of plasma membrane asymmetry 
(Martin et al., 1995). In apoptotic cells, the membrane phospholipid phosphatidylserine 
(PS) is translocated from the inner to the outer leaflet of the plasma membrane, thereby 
exposing PS to the external cellular environment (Martin et al., 1995). Detection of such 
membrane changes by Annexin V has been suggested as a suitable assay of early 
apoptotic cells. Annexin V is a 35 kDa, Ca2+-dependent phospholipid binding protein that 
has a high affinity for PS, and binds to cells with exposed PS (Martin et al., 1995). 
Annexin V FITC Staining is typically used in conjunction with a vital dye such as 
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propidium iodide (PI) or 7-Amino-Actinomycin (7-AAD) (Allen and Davies, 2007). This 
allows the identification of early apoptotic cells (PI negative, FITC Annexin V positive), 
viable cells (PI and Annexin V negative) and necrotic cells (PI and Annexin V positive) 
(Allen and Davies, 2007).  Our data showed that the extracts induced necrosis more than 
apoptosis in the U937 cells after 24 h exposure to Annexin V-FITC/PI. The high 
percentage of necrosis observed with the Annexin kit in this experiment correlates with 
the high level of cytotoxicity observed with the confluent Chang cell. Although, several 
studies have shown that Solanum alkaloids are not destroyed by boiling, baking, frying, 
or drying at high temperature (Bushway and Ponnampalam, 1981; Jadhav et al., 1997), it 
is worth noting that the cells treated with the boiled extracts had a lower percentage of 
necrosis compared to those treated with the fresh extracts. 
These results clearly demonstrate that extracts of Solanum aculeastrum was 
neither selective in the inhibition of carcinoma nor actively dividing and un-dividing 
cells. Although compounds found in S. aculeastrum are potent inhibitors of human 
carcinoma cells, it is still imperative to ascertain that any potent inhibitor of cancer cells 
must possess low IC50 values when tested against actively dividing cells and a high IC50 
values against confluent cells.  
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Figure 1: Comparative effect of boiling of the fresh and dried berries of Solanum 
aculeastrum on (a) HeLa; (b) HT-29; (c) MCF-7; (d) chang liver; (e) confluent 
chang liver cells. Mean ± SD (n = 4). Note: DB Dried berries; BDB Boiled dried 
berries; FB Fresh berries; BFB Boiled fresh berries 
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Table 1: IC50 values of the extracts of Solanum aculeastrum on some cell lines.  Values 
in parentheses represent the selectivity index, calculated by dividing the IC50 for 
confluent Chang liver cells for a specific extract by the IC50 for the cancer cell line for 
the same extract. 
 
Cell lines FB BFB DB BDB 
 
µg/ml 
HeLa 12.5 (2.6) 47.5 (0.84) 42.5 (1.12) 42.5 (1.12) 
HT-29  50.0 (0.65) 52.5 (0.76) 100.0 (0.48) 55.0 (0.86) 
MCF-7 12.5 (2.6) 42.0 (0.95) 45.5 (1.04) 47.5 (1.00)  
Normal cells  
   
Chang liver (log phase) 12.5  40.0 47.5 47.5  
Confluent Chang liver 32.5 40.0 45.0 50.0 
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Table 2: Apoptosis results from Annexin V-FITC/PI analysis using U937 leukemia cells 
 
 
Viable cells Early apoptotic Necrotic 
Treatment % % % 
Control 67.5 2.6 2.0 
Cisplatin (10 µM) 28.9 31.8 5.9 
Fresh berries 5.4 2.1 42.2 
Boiled fresh berries 25.5 7.7  20.7  
Dried berries 3.1 3.2 28.8 
Boiled dried berries 35.3 12.7 15.3 
 
 
*Extract concentration: 15.6 µg/mL 
*% DMSO: 0.5 
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CHAPTER 6 
 
 
Toxicological evaluation of the aqueous 
extract of the berries of Solanum 
aculeastrum Dunal. berries in male Wistar 
rats. 
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